Back Pain Doctor
Trigger Finger
Written by Dr Joshua Hatch, Musculoskeletal GP, RACGP Fellow, Diploma in Musculoskeletal Medicine (FSEM UK).
Trigger finger, or stenosing tenosynovitis, occurs when a finger or thumb catches or locks as it moves, because a flexor tendon can no longer glide freely through its pulley at the base of the digit. It is more common in people with diabetes or rheumatoid arthritis and in those who do repetitive gripping.
Assessment is usually clinical: the diagnosis can generally be made from the history and examination, and imaging is not routinely required. Where the diagnosis is uncertain, ultrasound can help.
Most cases respond to non-surgical care, including splinting, activity modification and an image-guided corticosteroid injection, which is often effective. If the finger is locked or injection does not help, referral for a trigger finger release is appropriate. Because trigger finger is linked with diabetes, its presence can be a useful prompt to review blood sugar control.
Common symptoms
- A tender lump at the base of a finger or thumb on the palm
- Catching, popping or locking when moving the finger
- A finger that gets stuck bent and has to be straightened with the other hand
- Stiffness that is worse in the morning and eases with use
Evidence for twelve treatment options in trigger finger
This is not a fixed ladder or a package of treatments. Every option is assessed independently against this diagnosis, including treatments with limited direct research that may still be reasonable for a clearly defined tissue target. The evidence level, likely benefit, risks, cost and alternatives are weighed at consultation.
Foundation: diagnosis, education and rehabilitation
The part of care with the broadest relevance. For many people it is enough on its own; other options are judged against it, not automatically added after it.
Diagnosis, education and progressive rehabilitation Working out what is driving the pain, explaining what your imaging does and does not mean, and building a graded loading plan you can actually follow. Core care
What it involves
Assessment to identify the likely pain source, an explanation of what the diagnosis means, adjustment of the loads that aggravate it, and a progressive strength and conditioning plan, with weight management where that is clinically relevant.
What the evidence shows
Loading is the treatment, and the trials say adjuncts add little to it. A living network meta-analysis of 68 randomised trials across Achilles and patellar tendinopathy and gluteal tendinopathy found no convincing evidence that any adjunct, alone or added to exercise, beats exercise by itself, and recommended exercise alone for at least three months before an adjunct is considered (Challoumas, Sports Med Open 2023). A meta-analysis of 110 studies and 3,953 patients found greater effect where the programme added external load rather than body weight alone, and where sessions were less frequent than daily, allowing recovery (Pavlova, Br J Sports Med 2023). A 204-study synthesis found exercise safe, beneficial and acceptable to patients, with no clear superiority for the eccentric-only protocols long treated as standard (Cooper, Health Technol Assess 2023).
Pairing reviewed 2026-09-02.
Where it fits
This is the plan, not the preliminary. Expect a programme measured in months rather than weeks, with load progressed against your symptoms. Anything else offered here is an adjunct to it, and the evidence for adding one before three months of proper loading is weak.
Muscle and symptom-modifying options
Useful only when the examination identifies the tissue they target or when short-term pain control creates a useful rehabilitation window.
Wet needling and trigger point injection (trigger point injection) A fine needle into a tender band of muscle, with a small volume of dilute glucose solution injected through it. Pulley needling only, one week
What it involves
The needle is placed into the tender muscle band and a small volume of 5% glucose with a very dilute local anaesthetic (0.02-0.08%) is injected. Often done in the same visit as your assessment, and usable where the tender area sits deeper. Dry needling (the same technique with nothing injected) is not offered here.
What the evidence shows
Searched 7 November 2026 (PubMed: trigger point, dry needling, wet needling, trigger point injection, myofascial or intramuscular stimulation with trigger finger or stenosing tenosynovitis, 7 records; and a randomised-trial and systematic-review pass). No study has injected a muscle trigger point in trigger finger. One 58-person randomised trial needled the A1 pulley and flexor tendon themselves, with nothing injected, against no treatment: pulley-tendon thickness, grip and DASH scores were better one week later, with no longer follow-up and no figures in the abstract (Azizian, J Phys Ther Sci 2019). That is needling of the pulley, not of a muscle band, and is not this treatment. The studied injection here is cortisone into the tendon sheath, which sits in the guided injection row.
Pairing reviewed 2026-11-07.
Where it fits
Triggering comes from the tendon catching at its pulley in the palm, not from a muscle knot, so a trigger point injection is rarely relevant. A sheath injection (see guided injection) or splinting are the established options.
Ultrasound-guided injections Guidance means the needle can be seen reaching the target. What goes into the needle depends on the diagnosis. Worth discussing
What it involves
The injection is performed under ultrasound so the needle can be watched into the target structure. What is injected is decided by the diagnosis, and corticosteroid is used sparingly, for the reasons set out below.
What the evidence shows
A randomised trial of 74 patients found ultrasound-guided and blind corticosteroid injection of the flexor sheath equally effective for pain and triggering at 6 weeks and 6 months (Çeçen, Arch Orthop Trauma Surg 2014). Injection itself works well here.
Pairing reviewed 2026-08-30.
Where it fits
Injection is a good option for trigger finger; guidance is not what makes the difference.
V-ACTOR vibration therapy (vibration therapy) Low-frequency vibration applied over tender muscle. Not a shockwave, despite sharing the machine. Plausible: no studies
What it involves
A vibration handpiece is moved over the tender muscle and fascia for a few minutes. It runs from the same STORZ MASTERPULS icon console as radial shockwave but is a separate handpiece delivering a different, gentler form of energy. No needles, no anaesthetic, no downtime.
What the evidence shows
No published clinical trial of this device in this condition. It is a vibration handpiece delivered from the same console as radial shockwave, and the rationale is myofascial rather than tendon- or bone-directed.
Pairing reviewed 2026-08-30.
Where it fits
A comfort measure used within a session where muscular tightness is limiting movement. Never the reason for the appointment, and not a substitute for the treatments that do have evidence.
Energy-based treatment options
Radial pressure wave, focused shockwave and EMTT have different targets and different evidence. They are assessed separately rather than treated as one category.
Radial or focused shockwave? Read the overviewRadial shockwave (radial pressure wave) Broad treatment across tender muscle and fascia, close to the surface. Non-randomised study and case series
What it involves
A handpiece is moved over the tender tissue while ballistic pressure pulses are delivered, using a transmitter head chosen for the tissue, including heads shaped for fascia and for the muscle either side of the spine. The pulse is strongest at the skin and weakens with depth, so this is mainly a myofascial treatment, though it can reach deeper in some areas. No anaesthetic, no downtime, usually a course of sessions about a week apart.
What the evidence shows
Searched 17 October 2026 (27 records, all read). The old line here said the trials used focused devices; that is true of the one sham-controlled trial (Chen, Arch Phys Med Rehabil 2021) but not of the rest. Radial devices have a non-randomised comparison and case series of their own. In 42 people treated in sequence, a steroid injection relieved pain faster at six weeks, radial shockwave did better at six months on pain, stiffness and function, and fewer people in the shockwave group went on to surgery by two years (Suárez Cabañas, Rev Esp Cir Ortop Traumatol 2026; J Hand Surg Eur 2026). Two uncontrolled series of 18 and 44 people improved over three and twelve months (Dogru, Cureus 2020; Malliaropoulos, Open Access J Sports Med 2016). No radial trial against sham was found. The pooled analyses that favour shockwave over a placebo injection (Chiang, Ann Phys Rehabil Med 2026) and find it level with steroid (Shen, Clin Rehabil 2020) do not separate the two devices.
Pairing reviewed 2026-10-17.
Where it fits
The tendon pulley sits close to the skin of the palm, within reach of a radial device. Worth discussing as an alternative to a steroid injection for triggering that is not locking, alongside splinting and tendon-gliding exercises; where the finger locks, release is the more reliable option.
Focused shockwave (ESWT) A true shock wave converging at depth: for tendon, joint, ligament and bone. Beat sham in one 60-person trial
What it involves
A focused system generates an acoustic shock wave that converges at a focal point set at a defined depth, concentrating the energy where the target is. This is the form used for tendon, joint, ligament and bone. Typically four to six sessions about a week apart, no anaesthetic and no formal downtime.
What the evidence shows
Searched 17 October 2026: shockwave, shock wave or ESWT with trigger finger, trigger digit, trigger thumb or stenosing tenosynovitis (27 records, all read). One double-blind trial used a wide-focused device: in 60 people with grade II triggering, four weekly high-energy sessions gave lower pain and better QuickDASH function than sham at six months, a lower-energy setting did not separate from sham, and no adverse effects were reported (Chen, Arch Phys Med Rehabil 2021); three letters followed, one headed 'Major concerns' (Ogihara, Arch Phys Med Rehabil 2022). Across the wider literature, where most trials do not name the device, a network meta-analysis of 27 trials found shockwave more often successful than a placebo injection (odds ratio 7.49, 95% CI 1.02 to 55.26, a wide interval) and no different from a steroid injection, with surgical release the most effective option (Chiang, Ann Phys Rehabil Med 2026). A trial of 40 people found shockwave level with a steroid injection at six months (Yildirim, J Hand Surg Eur 2016), and in a three-arm trial of 116 people high-intensity laser did better than shockwave, both added to home exercise (Çetin Duru, Rheumatol Int 2026).
Pairing reviewed 2026-10-17.
Where it fits
Worth discussing as an alternative to a steroid injection for triggering that is not locking, alongside splinting and tendon-gliding exercises. Where the finger locks or will not straighten, release is the more reliable option, and patients are told so.
EMTT (magnetotransduction therapy) High-energy magnetic pulses applied over the area. Usually painless, no contact. Plausible: no studies
What it involves
You sit with the applicator positioned over the area for a short session. It is usually painless and needs no gel or skin contact. It is usually given as a course, commonly alongside shockwave.
What the evidence shows
There are no published randomised trials of EMTT in this condition, or in any musculoskeletal condition, that could be identified. The supporting work is laboratory work: EMTT increased tenocyte proliferation, migration and collagen expression in cultured human tendon cells (Mancini, Int J Mol Sci 2025). The nearest human evidence for a related electromagnetic therapy is negative. A randomised trial of pulsed electromagnetic field therapy added to eccentric exercise for Achilles tendinopathy found no improvement in outcome scores or tendon neovascularity over eccentric exercise alone (Ko, Orthop J Sports Med 2024).
Pairing reviewed 2026-08-30.
Where it fits
Offered only as an adjunct alongside treatment that does have evidence, never as the plan itself, and only after that gap is explained. Much of the EMTT literature is manufacturer-affiliated, which is part of why it is described this way.
Biologic and joint injection options
Each injection is assessed independently for the named diagnosis. Cost, uncertainty, likely benefit, risks and alternatives are part of the decision.
Platelet-rich plasma (PRP) Your own blood, concentrated and injected under ultrasound guidance. One case report only
What it involves
Blood is taken from your arm, spun to concentrate the platelets, and injected into the target under ultrasound guidance in the same appointment.
What the evidence shows
Searched for PRP in trigger finger and trigger thumb. Nineteen records across the hand tendon conditions, and a randomised-trial pass, contained no trial in this condition. The only clinical report is a single case, a 63-year-old woman whose triggering resolved after three injections over two weeks and had not returned at three months (Medina-Porqueres, Agri 2022). A three-arm blinded trial of PRP, cortisone and saline was registered in Helsinki (Aspinen, Trials 2020); no results from it were found on PubMed in October 2026.
Pairing reviewed 2026-10-09.
Where it fits
Not something to choose ahead of the established options. Splinting, a cortisone injection and, where those fail, a small release procedure are the usual treatments for a trigger finger. PRP can be discussed only on the understanding that it rests on one published case.
Prolotherapy (dextrose) A course of dextrose injections into and around the structure and its attachments. Case reports only
What it involves
Hypertonic dextrose is injected at the tender ligament and tendon attachments, and into the joint where relevant, usually as a series of treatments a few weeks apart.
What the evidence shows
No trial of prolotherapy in trigger finger was found. A PubMed search on 13 October 2026 (prolotherapy, dextrose or hypertonic glucose with trigger finger, stenosing tenosynovitis or de Quervain) returned seven records, and passes restricted to randomised trials and to systematic reviews or meta-analyses found nothing in this condition. The clinical records are three case reports. Two, from one group, describe triggering that resolved after ultrasound-guided prolotherapy in unusual variants: a calcium deposit in the A1 pulley, treated with three sessions alongside physiotherapy and night splinting, and a problem where the flexor tendons attach to the finger bones that had not responded to cortisone (Yoon, Cureus 2025, two reports). The third is a harm report: a man whose triggering worsened after repeated prolotherapy needed surgery to remove a large fibrous nodule on the pulley and an inflamed tendon sheath (Oh, J Surg Case Rep 2023). A 2026 review puts prolotherapy forward only as a hypothesis to be tested for the tendon-dominant pattern (Kim, Life 2026).
Pairing reviewed 2026-10-13.
Where it fits
Not a first-line option: cortisone injection and, where needed, release of the pulley are the treatments with trial evidence. Can be discussed for an unusual pattern on ultrasound where the problem is not the classic pulley narrowing, with the case-report-only evidence and the reported harm stated.
Viscosupplementation (hyaluronic acid) A gel-like injection into an arthritic joint. Widely used, and genuinely contested. Not used for tendons
What it involves
One or a short series of hyaluronic acid injections into the joint under ultrasound guidance.
What the evidence shows
Not offered here. A meta-analysis of 19 randomised trials of hyaluronic acid in soft-tissue problems, 1,629 patients in all, reported less pain than the comparison treatments overall, but its trigger finger group was two trials with uncertain benefit (Khan, Sports Health 2022). These are injections around a tendon, which is a different procedure from the joint injection in this row.
Pairing reviewed 2026-10-05.
Where it fits
Not offered for this problem. Hyaluronic acid is considered only for a problem inside a joint, and trigger finger is a tendon and pulley problem.
Nerve-targeted options
Relevant when examination identifies a superficial neuropathic pattern or a compressed peripheral nerve, not simply because pain is present.
Lyftogt perineural therapy (perineural injection therapy) A series of small dilute dextrose injections just under the skin, over tender superficial nerves. Different injection target
What it involves
Small injections of low-concentration dextrose, usually 5%, placed just beneath the skin along tender superficial nerves. Given as a series of short sessions.
What the evidence shows
The dextrose evidence at this finger goes into the tendon or the pulley, not under the skin. Two case reports describe ultrasound-guided prolotherapy resolving the triggering completely: two sessions into the flexor tendon entheses in a 61-year-old whose problem was insertional tendinopathy rather than the A1 pulley, and three sessions where a calcium deposit sat in the A1 pulley itself (Yoon, Cureus 2025, two reports). A review of ultrasound phenotypes lists prolotherapy and hydrodissection among the adjuncts for tendon-dominant patterns, explicitly as a hypothesis rather than a validated pathway (Kim, Life 2026). None of that is a series of small injections just under the skin over a nerve. The search also returns a harm report: repeated prolotherapy at the A1 pulley left a 47-year-old with worse flexor tenosynovitis and a firm fibrous nodule that had to be surgically removed (Oh, J Surg Case Rep 2023).
Pairing reviewed 2026-09-28.
Where it fits
Considered only where examination finds tender, hypersensitive skin over the palm rather than a catching tendon. The triggering itself is mechanical, at the pulley, and this treatment does not address it.
Ultrasound-guided nerve hydrodissection Fluid placed around a nerve to free it from the surrounding tissue. Plausible: no studies
What it involves
Under ultrasound, fluid is placed in the plane around the nerve to separate it from the tissue that is tethering or compressing it.
What the evidence shows
No trial of hydrodissection in trigger finger. A review synthesising the 2010–2025 literature proposes it as an adjunct for the tendon-dominant pattern rather than the classic A1 pulley bottleneck, but presents that framework explicitly as a hypothesis to be tested rather than a guideline (Kim, Life 2026). Beyond it the literature is a single case report: a 25-year-old cook with triggering and normal A1 pulleys whose symptoms resolved after 5% dextrose hydrodissection at an unstable flexor digitorum superficialis in the forearm (Yoon, Cureus 2026). A review of ultrasound-guided wrist and hand procedures describes hydrodissection only for carpal tunnel syndrome (Mezian, Acta Chir Orthop Traumatol Cech 2025).
Pairing reviewed 2026-09-08.
Where it fits
Not a first-line option. Relevant mainly where ultrasound does not show the expected A1 pulley problem and the triggering appears to come from higher up the tendon: an uncommon picture, and one where the published evidence is a single reported case.
This is general information only and suitability is assessed individually. Treatments with limited or condition-dependent evidence may still be discussed, but only with clear explanation of the uncertainty, the expected benefit, risks, cost and alternatives. Red flags, progressive neurological symptoms or suspected serious pathology require a different pathway.
Every treatment above is described in full on the non-surgical treatments page, including what each one is used for and what the evidence supports. Ratings apply to the named diagnosis; an adjacent muscle, tendon, joint or nerve problem is assessed as a separate target. The method behind the ratings, and the treatments not offered, are set out on the evidence page.
Corticosteroid injection is reviewed separately for each diagnosis.
Cortisone reliably reduces pain in the short term, and that can be genuinely useful when pain is stopping you sleeping or moving enough to rehabilitate. Beyond that window the picture changes. A systematic review of 41 randomised trials and 2,672 participants found that corticosteroid injection reduced pain in the short term but that the effect reversed at intermediate and long term; in pooled analysis for lateral epicondylalgia the short-term effect was large (SMD 1.44, 95% CI 1.17 to 1.71) while no intervention was favoured at 26 weeks (-0.40, -0.67 to -0.14) and at 52 weeks (-0.31, -0.61 to -0.01) (Coombes, Lancet 2010). In a randomised trial in lateral epicondylalgia, 83 per cent of the corticosteroid group had completely recovered or much improved at one year against 96 per cent given a placebo injection, and recurrence ran at 54 per cent against 12 per cent; adding physiotherapy made no significant difference at one year (Coombes, JAMA 2013). In joints, repeated corticosteroid injections have been associated with cartilage loss. It does not repair anything.
So treatment plans are not built around it. Where an injection is the right call, the specific diagnosis and target are reviewed, what is being injected and why is discussed, the number is kept low, and it is paired with the loading work that changes the longer-term course.
When it might still be considered
- Pain severe enough to block rehabilitation
- A clear inflammatory or bursal target on imaging
- A specific short-term goal: a trip, a procedure, a return to work
- Diagnostic use, where the response shows where the pain is coming from
When a cortisone injection is worth doing, and when it is not
Other elbow, wrist & hand conditions
Pain in the same area can come from more than one source, and the label matters less than what the examination and history point to. These are the other guides for this region.
Related articles
Shorter articles that answer the questions patients ask most often about this.
Frequently asked questions
What causes trigger finger?
How is it treated without surgery?
When is surgery needed?
Ready for a clearer plan for your back or musculoskeletal pain?
Book an assessment with Dr Joshua Hatch.
Your assessment focuses on understanding the likely source of your pain and the most appropriate non-surgical options for your diagnosis, with the aim of reducing pain and improving function.
You must have your own regular GP before booking. This service works alongside your GP for focused care. Booking requirements.
Book an appointment